SCHEMBL3099986

SCHEMBL3099986

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccccc2OC)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.52
THRB P10828 1/20 0.50
RXFP1 Q9HBX9 3/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
KCNA5 P22460 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092938 0.93 MEN1 (0.45) KAT6ATHRBRXFP1RAB9ANPC1
SCHEMBL3088121 0.93 ALOX15 (0.43) KAT6ATHRBRAB9ANPC1MAPT
SCHEMBL3093284 0.89 KAT6A (0.49) KAT6ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3093039 0.89 MEN1 (0.50) KAT6ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3100199 0.88 NPC1 (0.53) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL3100518 0.88 NPC1 (0.51) KAT6ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3101165 0.88 NPC1 (0.51) KAT6ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3096503 0.88 LARS1 (0.45) KAT6ANPC1MAPTALDH1A1MEN1
SCHEMBL3086202 0.88 SMO (0.46) KAT6ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL15000205 0.88 MEN1 (0.46) KAT6ARAB9ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 KAT6A 3337/4885THRB 908/4885RXFP1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.